Search Results - Kenneth W. Mahaffey

Refine Results
  1. 1
    Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment

    Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment by Byron Cryer, Kenneth W. Mahaffey

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Management of Patients With NSTE-ACS

    Management of Patients With NSTE-ACS by Fátima Rodríguez, Kenneth W. Mahaffey

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    <p>Canagliflozin review – safety and efficacy profile in patients with T2DM</p>

    <p>Canagliflozin review – safety and efficacy profile in patients with T2DM</p> by Haroon Jakher, Tara I. Chang, Marilyn Tan, Kenneth W. Mahaffey

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY

    Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY... by Jinnie J. Rhee, Meg Jardine, Glenn M. Chertow, Kenneth W. Mahaffey

    Published 2020
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Characteristics of Digital Health Studies Registered in ClinicalTrials.gov

    Characteristics of Digital Health Studies Registered in ClinicalTrials.gov by Connie Chen, Robert A. Harrington, Sumbul Desai, Kenneth W. Mahaffey, Mintu P. Turakhia

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

    Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review by Karin Rådholm, Jason Wu, Muh Geot Wong, Celine Foote, Gregory Fulcher, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Reviewing the role of healthy volunteer studies in drug development

    Reviewing the role of healthy volunteer studies in drug development by Joyson Karakunnel, Nam Q. Bui, Latha Palaniappan, Keith T. Schmidt, Kenneth W. Mahaffey, Briggs Morrison, William D. Figg, Shivaani Kummar

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection

    Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection by Roham T. Zamanian, Charles V. Pollack, Michael A. Gentile, Moira Rashid, J. Christian Fox, Kenneth W. Mahaffey, Vinicio de Jesús Pérez

    Published 2020
    Get full text
    Carta
    Save to List
    Saved in:
  9. 9
    The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the <scp>CANVAS</scp> and <scp>CREDENCE</scp> Trials

    The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the <scp>CANVAS</scp> and <scp>CREDENCE</scp> Trials by Tu Ngoc Nguyen, Jie Yu, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey, Clara K Chow, Clare Arnott, Richard I. Lindley

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials

    Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials by Zubin J. Eapen, W.H. Wilson Tang, G. Michael Felker, Adrian F. Hernandez, Kenneth W. Mahaffey, A. Michael Lincoff, Matthew T. Roe

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes by Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R. Matthews

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Glucose, insulin, and acute myocardial infarction: reply

    Glucose, insulin, and acute myocardial infarction: reply by Abhinav Goyal, Kenneth W. Mahaffey, Jyotsna Garg, José Carlos Nicolau, Judith S. Hochman, W. Douglas Weaver, Gustavo B.F. Oliveira, Thomas T. Todaro, Christopher B. Granger

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion

    Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion by Matthew T. Roe, E. Magnus Ohman, Arthur Maas, Robert H. Christenson, Kenneth W. Mahaffey, Christopher B. Granger, Robert A. Harrington, Robert M. Califf, Mitchell W. Krucoff

    Published 2001
    Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

    Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus by Gemma A. Figtree, Karin Rådholm, Terrance D. Barrett, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, David R. Matthews, Wayne Shaw, Bruce Neal

    Published 2019
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  15. 15
    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes by Jingwei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L. Neuen, Clare Arnott, Robin Simpson, Richard Oh, Kenneth W. Mahaffey, Hiddo J.L. Heerspink

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide

    Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide by James L. Januzzi, Jialin Xu, Jingwei Li, Wayne Shaw, Richard Oh, Roman Pfeifer, Javed Butler, Naveed Sattar, Kenneth W. Mahaffey, Bruce Neal, Michael K. Hansen

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin

    Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin by Muthiah Vaduganathan, Naveed Sattar, Jialin Xu, Javed Butler, Kenneth W. Mahaffey, Bruce Neal, Wayne Shaw, Norman Rosenthal, Roman Pfeifer, Michael K. Hansen, James L. Januzzi

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

    Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure by Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo J.L. Heerspink

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes

    Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes by Daniel Lindholm, Stefan James, Katja Gabrysch, Robert F. Storey, Anders Himmelmänn, Christopher P. Cannon, Kenneth W. Mahaffey, Philippe Gabríel Steg, Claes Held, Agneta Siegbahn, Lars Wallentin

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

    Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial by Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse, Gary Meininger, David R. Matthews

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: